Kornimate/medical-research-clean huggingface dataset:
motor imagery in healthy individuals

Conditions: Health, Subjective

Summary: the research will be the first to examine the relationship between mental fatigue induced by motor imagery and upper extremity performance. this study, it is aimed to examine whether the effects of mental fatigue created by motor imagery on upper extremity performance can be reduced by diaphragmatic breathing exercises.


Eligibility criteria:
inclusion criteria: * right-handed dominance (it will be decided according to edinburgh hand questionnaire result) * volunteer to participate in the study. * to be sedentary * not having any problems that prevent breathing exercises * be between the ages of 18-30 exclusion criteria: * have any mental or sensory problems in the past 6 months * presence of acute infection or chronic disease of neurological, psychiatric, orthopedic, cardiological, rheumatological, etc. * having had covid-19 * having any respiratory disease (asthma, copd, etc.) * having any upper extremity injury and/or operation (trauma, surgery, fracture, etc.) in the -last 6 months doing regular exercises (at least 30 minutes a day / 5 times a week for a total of at least 150 minutes) * be on regular medication * be smoking

Keywords: motor imagery mental fatigue diaphragmatic breathing exercises
df-life : quality of life in patients with fibrous dysplasia

Conditions: Fibrous Dysplasia

Summary: fibrous dysplasia (fd) is a congenital skeletal disorder with multiple complications such as bone pain, fractures, deformities and nerve compression. few quantitative studies have demonstrated its physical, mental and social negative impacts on patients but none have qualitatively evaluated their global quality of life. our hypothesis is that a better knowledge of the quality of life of fd patients should allow to target the actions to be implemented to improve patients'care. the main objective of this qualitative research is therefore to investigate the quality of life of fd patients through 2 approaches: a qualitative study with focus groups interviews addressing several themes: self-image, psychological and emotional well-being, difficulties and adaptative strategies; and a quantitative study to measure the impact of fd on quality of life and on olfaction (sometimes affected by nerve compression due to the disease) using standardized questionnaires short form 36 (sf36) and self-reported mini olfactory questionnaire (self-moq).


Eligibility criteria:
inclusion criteria: * men and women * 18 years and more * with fibrous dysplasia * being followed in the rheumatology department of the e. herriot hospital in lyon. * non-opposition to take part in the study * written consent to the audio recording of the discussions. exclusion criteria: * legal incapacity or limited legal capacity * psychiatric or neurological condition that severely impairs comprehension * difficulty understanding spoken french * patients with another pathology with a major impact on quality of life

Keywords: fibrous dysplasia quality of life
nstride aps in females with primary patellofemoral osteoarthritis

Conditions: Patellofemoral Osteoarthritis

Summary: the purpose of this study is to evaluate clinical outcomes following a single injection of nstride autologous protein solution in females with isolated patellofemoral osteoarthritis. a secondary objective of this study is to document the duration of treatment effect following nstride injection.

clinical trials have, in general, formally demonstrated the effectiveness and safety of various autologous therapies for the treatment of knee oa. differences in the processing of autologous therapies can yield substantial differences in the resulting output. thus, making generalizations regarding the effectiveness across these autologous therapies is more complicated. each autologous therapy requires independent efficacy evaluation. nstride aps has been shown to decrease pain, increase function and have a favorable safety profile in a pilot trial. further, demonstration of the treatment effects in patellofemoral osteoarthritis, an important subset of knee osteoarthritis is lacking. this study will evaluate a population of female patients with patellofemoral osteoarthritis in which treatment with other modalities provides limited/short lived relief with the hope that aps treatment will provide and extend relief to these patients. the study will document the treatment effects and timeline of treatment effects for nstride aps following a single injection (per symptomatic knee).

Eligibility criteria:
inclusion criteria: * patient must be female * isolated patellofemoral osteoarthritis (pfoa) in one or both knees as diagnosed by the treating physician * objective evidence of pfoa on one or both of a radiograph or mri taken within 3 months of treatment * from 40-65 years of age, inclusive at time of injection * symptoms return such that there is a need for further treatment within 3 months of a corticosteroid or hyaluronic acid injection * willing and able to comply with the study procedures * sign informed consent form exclusion criteria: * any systematic inflammatory condition (e.g. rheumatoid arthritis) * active malignancy at time of injection * pregnant at time of injection * lactating at time of injection * knee joint infections or skin diseases or infections in the area of the injection site * leukemia, metastatic malignant cells, or who are receiving chemotherapeutic treatment * participation in another device, biologic or drug study

Keywords: autologous protein solution patellofemoral osteoarthritis female
pharmacomri of parkinson disease

Conditions: Parkinson's Disease

Summary: based on studies showing better responsiveness of motor versus cognitive symptoms to parkinson's disease medication, also known as dopaminergic treatments, the investigators hypothesize that comparison of resting state networks in the on versus off medication state in parkinson's disease patients will show greater effects on brain networks associated with motor control.

subject participation includes two 25-30 minute mri scans. the subject will arrive in the "off" state (pd medications withheld for approximately 12 hours prior to the scan). following the initial scan, the subject will receive 125% of his or her usual daily morning dose of pd medications which is calculated as levodopa dose equivalents (lde) and is given as carbidopa-levodopa. the subject will then wait for an hour allowing for the medication to begin working. during this time the subject will complete cognitive assessments, questionnaires regarding the history and current state of pd, and motor assessments. the subject will then undergo a second mri scan of approximately 25-30 minutes. the subject after completing the second mri scan is free to leave. the entire study is approximately 2 and 1/2 hours long.

Eligibility criteria:
inclusion criteria: * idiopathic parkinson's disease (pd) * older than 30 years of age at the time of diagnosis * hoehn and yahr stage greater than or equal to 2.5 * pd duration greater than 3 years * stable regimen of pd medications for at least 2 weeks prior to imaging * pd medications include carbidopa-levodopa exclusion criteria: * patients with a diagnosis of other neurodegenerative conditions * patients unwilling or unable to give informed consent * contraindications (cardiac pacemaker, etc.) or inability (e.g., claustrophobia) to undergo mri scan
escitalopram treatment in acute stroke

Conditions: Stroke

Summary: growing international scientific evidence has indicated a positive effect of ssri treatment (serotonin reuptake inhibitors) after stroke, beyond its antidepressant effect. we wish to conduct a prospective randomised double blind placebo-controlled multicenter study of the combined neuroprotective and antithrombotic effects of ssri treatment after stroke. deletion of the sert (serotonin transporter) gene may influence this treatment effect and may in itself be a risk factor for stroke, an aspect we also wish to explore. hypotheses: 1. ssri treatment commenced in the acute phase of stroke (day 2-5) protects against new thromboembolic events and leads to better rehabilitation. 2. a specific sert genotype is associated with an increased risk of first ever stroke. 3. a specific sert genotype is associated with a higher risk of post stroke depression. 600 stroke patients will be randomised to either escitalopram or placebo treatment in a 1:1 ratio and genotyped according to sert polymorphisms. the treatment and follow up period is 6 months. during these 6 months there will be 2 clinical follow up visits, one telephone control and one visit to evaluate compliance regarding medication. patients who had an mri as a part of the routine investigations done upon admission (approximately 300 patients) will have a control mri after 6 months. additionally 400 patients, not eligible for participation i the randomised controlled trial, will be genotyped and answer questionnaires after 1 and 6 months.


Eligibility criteria:
inclusion criteria: * first ever ischemic stroke * age 18 years or above exclusion criteria * hemorrhagic stroke * dementia or other neurodegenerative disease * antidepressant treatment within 6 months of admission * acute need for antidepressant treatment * drug abuse or other conditions that may indicate noncompliant behavior * liver failure (increased liver enzyme levels up to or more than 2 times upper limit) * renal failure (gfr under 30) * hyponatremia (s-potassium below 130 mmol/l) * actively bleeding ulcer * fatal stroke or other severe co morbidity that markedly decreases expected life span * prolonged qt interval (qtc above 500 ms) * ongoing treatment with drugs known to prolong the qt interval

Keywords: stroke rct ssri outcome
the effects of lipoic acid on glycaemic control in type 2 diabetes

Conditions: Diabetes Mellitus, Type 2

Summary: hypothesis: that lipoic acid supplements taken orally will improve control of blood sugar levels in people with type 2 diabetes. this study will recruit 18 people with type 2 diabetes, whose diabetes is currently managed on oral agents. each subject will then either take placebo for 12 weeks followed by lipoic acid for 12 weeks, or lipoic acid followed by placebo. a blood test for overall diabetes control will be taken at the start and end of each 12 week period, and the change in control will be compared for lipoic acid vs placebo.

this is a randomized, double-blinded, placebo-controlled crossover trial of lipoic acid for glycaemic control in type 2 diabetes. the trial has 3 phases, each lasting 12 weeks. during phases 1 and 3, subjects take lipoic acid or placebo tablets, the order to be determined by randomization. phase 2 is a 12-week washout period. the intervention is lipoic acid 200mg daily for 1 week, 400mg daily for the second week, and 600mg daily for weeks 3-12. equivalent numbers of placebo tablets will be taken during the placebo phase. the principal outcome measure is change in hba1c between the start and end of lipoic acid supplementation, by comparison with the same change with placebo. the secondary outcome measure is change in urine albumin:creatinine ratio over the same periods. assessments for safety will include standard adverse events reporting, repeated laboratory measurements throughout the study (blood count, renal and liver function) and hypoglycaemia frequency.

Eligibility criteria:
inclusion criteria: * type 2 diabetes * age \> 18 years * capable of giving informed consent * treated with oral antidiabetic agents (not insulin) * hba1c 7.0 - 8.5% at last measurement (must be within 6 months of study) * most recent hba1c within 1% of all measurements within preceding year * prepared to self-test blood glucose on a regular basis * prepared to use contraception during study if of child-bearing potential exclusion criteria: * unstable cardiac disease (nyha class iii or iv heart failure, or unstable angina or myocardial infarction within last three months) * significant renal or hepatic impairment (creatinine\>170 micromol/l, alanine transaminase or alkaline phosphatase \> 3x upper limit of normal) * other medical condition or treatment likely to affect glycaemic control * previous history of significant hypoglycaemia * pregnancy * involvement in other clinical trial in last three months * known or suspected sensitivity to trial products

Keywords: type 2 diabetes mellitus glycaemic control lipoic acid diabetic nephropathy
south korean study to prevent cognitive impairment and protect brain health through lifestyle intervention

Conditions: Mild Cognitive Impairment; Aged

Summary: this study evaluates acceptability and efficacy of multidomain intervention program to prevent cognitive impairment and protect brain health in korean at-risk elderly. a third of participants will receive facility-based intervention for 6 months, a third will receive home-based intervention for 6 months, and a third is waiting list controls.

despite extensive research in the field of alzheimer's disease (ad), no treatment has yet been developed to modify the progression of ad. therefore, it is important to manage vascular and metabolic risk factors, to eat healthy foods, to exercise, and to participate in social activities to prevent dementia. the finger study showed that the multi-domain intervention program is effective to prevent cognitive impairment and disability in elderly. in south korea, exercise and leisure programs, and brain activity for the elderly also have been conducted in welfare centers and public health centers. however, there are not enough programs that have proven effective in the studies. so the investigators would like to develop a multi-domain intervention program and investigate applicability and efficacy before a large-scale randomized controlled trial.

Eligibility criteria:
inclusion criteria: 1. aged 60-79 2. having at least one among the following dementia risks, * hypertension * diabetes mellitus * dyslipidemia * obesity * abdominal obesity * metabolic syndrome * smoking * educational level ≤ 9 years * physical inactivity * social inactivity 3. independent activities of daily living 4. mini-mental state examination score better than1.5 standard deviations below age and education-adjusted normative means 5. can read and write korean 6. having a reliable informant who could provide investigators with the requested information. 7. provide written informed consent exclusion criteria: 1. major psychiatric illness such as major depressive disorders 2. dementia 3. substantial cognitive decline 4. other degenerative disease (e.g., parkinson's disease) 5. malignancy within 5 years 6. cardiac stent or revascularization within 1 year 7. serious or unstable symptomatic cardiovascular disease 8. other serious or unstable medical disease such as acute or severe asthma, active gastric ulcer, severe liver disease, or severe renal disease 9. severe loss of vision, hearing, or communicative disability 10. any conditions preventing cooperation as judged by the study physician 11. significant laboratory abnormality that may result in cognitive impairment 12. unable to participate in exercise program safely 13. coincident participation in any other intervention trial

Keywords: prevention dementia intervention mild cognitive impairment
irinotecan in treating patients with newly diagnosed ewing's sarcoma

Conditions: Sarcoma

Summary: rationale: drugs used in chemotherapy, such as irinotecan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. purpose: this phase ii trial is studying how well irinotecan works in treating patients with newly diagnosed ewing's sarcoma.

objectives: primary * assess the responsiveness of single-agent irinotecan hydrochloride in a patient population with newly diagnosed high-risk ewing's sarcoma. outline: this is an open-label, multicenter study. patients receive irinotecan hydrochloride iv over 1 hour on day 1. treatment repeats every 21 days for 2 courses. after completion of 2 courses of therapy, patients may receive additional treatment at the discretion of the treating physician. after completion of study treatment, patients are followed periodically. projected accrual: a total of 35 patients will be accrued for this study.

Eligibility criteria:
disease characteristics: * histologically confirmed ewing's tumor * ewing's sarcoma or peripheral primitive neuroectodermal tumor of bone or soft tissue * high-risk disease (r3), defined as metastases at extrapulmonary/pleural sites * newly diagnosed disease * measurable primary and/or metastatic disease * at least one bidimensionally measurable lesion * concurrent enrollment on euro-ewing99 clinical trial required patient characteristics: * no abnormal cardiac function, including any of the following: * fractional shortening \< 29% * ejection fraction \< 40% * glomerular filtration rate ≥ 60ml/min * not pregnant * negative pregnancy test * fertile patients must use effective contraception during and for 3 months after completion of study treatment * no prior or current history of chronic diarrhea, bowel obstruction, sub obstruction, crohn's disease, or ulcerative colitis * no other medical, psychiatric, or social condition incompatible with the study treatment prior concurrent therapy: * no prior chemotherapy * no more than 45 days since prior definitive biopsy

Keywords: metastatic ewing sarcoma/peripheral primitive neuroectodermal tumor
personalized prevention of depression in primary care

Conditions: Depression

Summary: the main goal is to design, develop and evaluate a personalized intervention to prevent the onset of depression based on information and communications technology (icts), risk predictive algorithms and decision support systems (dss) for patients and general practitioners (gps). the specific goals are 1) to design and develop a dss, called e-predictd-dss, to elaborate personalized plans to prevent depression; 2) to design and develop an ict solution that integrates the dss on the web, a mobile application (app), the risk predictive algorithm, different intervention modules and a monitoring-feedback system; 3) to evaluate the usability and adherence of primary care patients and their gps with the e-predictd intervention; 4) to evaluate the effectiveness of the e-predictd intervention to reduce the incidence of major depression, depression and anxiety symptoms and the probability of major depression next year; 5) to evaluate the cost-effectiveness and cost-utility of the e-predictd intervention to prevent depression. methods: this is a randomized controlled trial with allocation by cluster (gps), simple blind, two parallel arms (e-predictd vs "active m-health control") and 1 year follow-up including 720 patients (360 in each arm) and 72 gps (36 in each arm). patients will be free of major depression at baseline and aged between 18 and 55 years old. primary outcome will be the incidence of major depression at 12 months measured by cidi. as secondary outcomes: depressive and anxiety symptomatology measured by phq-9 and gad-7 and the risk probability of depression measured by predictd algorithm, as well as cost-effectiveness and cost-utility. the e-predictd intervention is multi-component and it is based on a dss that helps the patients to elaborate their own personalized depression prevention plans, which the patient approves, and implements, and the system monitors offering feedback to the patient and to the gps. it is an e-health intervention because it is based on a web and m-health because it is also implemented on the patient's smartphones through an app. in addition, it integrates a risk algorithm of depression, which is already validated (the predictd algorithm). it also includes an initial gp-patient interview and a specific training for the gp. finally, a map of potentially useful local community resources to prevent depression will be integrated into the dss.


Eligibility criteria:
inclusion criteria: * phq-9 \<10 at baseline * moderate-high risk of depression (predictd risk algorithm score ≥ 10%) exclusion criteria: * not have a smartphone and internet for personal use * unable to speak spanish * documented terminal illness * documented cognitive impairment * limiting sensory disorder (e.g. deafness) * documented serious mental illness (psychosis, bipolar, addictions, etc.)

Keywords: depression primary prevention primary health care randomized controlled trial mhealth app
infrared choroidal reflectance camera for the detection of childhood cataract

Conditions: Childhood Cataract

Summary: sensitivity and specificity of current screening methods for childhood cataracts is poor. this results in delayed diagnosis and management which can decrease the visual prognosis following cataract surgery. it also results in many false positives with resultant unnecessary healthcare costs in specialist paediatric ophthalmology services. this study compares the accuracy of cataract screening using infrared light compared to white light in a population of children attending eye clinic.

all babies born in the united kingdom (uk) undergo eye screening to enable the early diagnosis and management of childhood cataract, a treatable but potentially blinding condition affecting 1 in 2000 newborns. the current technique involves the assessment of the "red-reflex" - the orange/red glow in the pupil seen during ophthalmoscopy (or flash photography) due to reflectance of light from the back of the eye. in reality, testing can be technically difficult because the pupil constricts to light during the examination and, particularly in babies of asian and afro-caribbean ancestry, the red-reflex can be dim due to the effect of ocular pigmentation. as a result less than 50% of congenital cataracts are currently identified up by screening. early visual experience is required for good visual development and a delay in the surgical management of cataracts results in sub-optimal visual development and visual impairment. there are theoretical advantages to using infrared (ir) light rather than white light to assess choroidal reflectance, including avoidance of pupil constriction. the study aims to determine if the assessment of the ir-reflex, using a prototype device, rather than the red-reflex, using a direct ophthalmoscope, improves screening accuracy in the detection of ocular media opacities in a pathology enriched childhood cohort. eligible children attending an eye clinic will be screened for cataract by a medical student (masked to the pathology) using the existing standard direct ophthalmoscope technique for red-reflex assessment and ir-reflex assessment using the prototype imaging device. a gold standard examination by an ophthalmologist will follow the screening examinations. sensitivity and specificity of each screening technique will be calculated and compared.

Eligibility criteria:
inclusion criteria: * all children between 1 month and 5 years of age attending paediatric ophthalmology clinic exclusion criteria: * parents / carers with poor conversant english